Fresenius Kabi has entered into an agreement to acquire Fenwal, Inc., a global provider specializing in separation technologies for blood and cell collection and therapy. Fresenius aims to offer customers a wider array of products and services, as well as increase product development and geographic expansion. The acquisition, subject to customary conditions, is expected to close by the end of the year. Financial terms were not disclosed.
“Fenwal has built a leadership position centered on separation technology used to collect and process blood and to treat disease,” said Rainer Baule, chairman and chief executive officer of Fresenius Kabi. “Like Fresenius Kabi, Fenwal has a unique and long history serving health care, productive relationships with customers and researchers, and a rich pipeline of new products that are essential to patients and those who care for them.”
“The products, services, technologies and cultures of both companies fit extremely well together,” said Ron Labrum, Fenwal president and chief executive officer. “We are committed to assuring a smooth integration with Fresenius Kabi and to bringing our customers even more value as a result of this unique combination.”